RxDoctor Payments Data

Kelsey Pasch, MD

Rheumatology · Baton Rouge, LANPI 1023578028

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.8% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 35.4% of the total. 2025 is the largest year on record at $2,807, more than ten times the $12 reported in 2020. That places this record below the midpoint for rheumatology clinicians in LA, where the typical reported total is $8,351.

$6,940in general payments, 2019–2025

Across 266 payments — averaging $26.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • UCB, Inc.$1K
  • Novartis$401
  • Johnson & Johnson$314
  • Janssen Scientific Affairs, LLC$301
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$6,65296%
  • Education$2884%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,940 in reported general payments places this provider in the 40th percentile of 88 rheumatology providers in Louisiana.

See all rheumatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$31,333
Medicare patients
82
Services billed
1,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib20$136,570
Orencia ClickjectAbatacept16$95,407
Hydroxychloroquine Sulfate222$4,976
Mycophenolate Mofetil51$3,952
MethotrexateMethotrexate Sodium145$1,560
Colchicine27$1,069
Leflunomide41$995
Prednisone119$598
Sulfasalazine18$435
Diclofenac Sodium14$400
Gabapentin29$340
Duloxetine Hcl19$260
Azathioprine13$247
Tramadol Hcl30$234
Allopurinol29$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,454$136,57020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 88 rheumatology providers in Louisiana.

Other rheumatology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →